Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Completed · Phase 3

Conditions studied: Type 1 Diabetes Mellitus

In brief

Primary Objective: To demonstrate similarity in pharmacokinetics (PK) of SAR341402 and NovoLog after 4x4-week periods of alternating administration of SAR341402 and NovoLog compared to 16-week continuous use of NovoLog in participants with Type 1 diabetes mellitus (T1DM) also using insulin glargine. Secondary Objectives: * To compare the effects of alternating administration of SAR341402 and NovoLog with continuous use of NovoLog on immunogenicity. * To evaluate the safety of alternating administration of SAR341402 and NovoLog versus continuous use of NovoLog. * To compare other PK parameters between the two treatment arms (alternating administration of SAR341402 and NovoLog and continuous use of NovoLog).

Key facts

Study ID

NCT03874715

Run by

Sanofi

People needed

210

Starts

2019-03-11

Expected to finish

2020-07-08

Last updated by the study team

2024-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with T1DM.
• Participants on continuous insulin treatment for at least 12 months prior to screening.
• Participants exclusively on a multiple (greater than or equal to 3) daily injection insulin analogue regimen using:
• NovoLog as mealtime insulin for at least 12 weeks prior to screening and
• Insulin glargine (100 units per milliliter [U/mL]) as basal insulin for at least 12 weeks prior to screening. Note: Participants not meeting this criterion could also qualify, provided that they completed the run-in period during which NovoLog and Lantus was administered so that, at the time of randomization, the participants had been on NovoLog and insulin glargine (100 U/mL) for at least 12 weeks (including any potential pre-screening administration).
• Glycated hemoglobin (HbA1c) less than or equal to 10 percent (%) (85.79 millimoles per mole) at screening.
• Body mass index less than or equal to 35 kilograms per meter square (kg/m\^2) at screening.

You may not qualify if…

• Pancreatectomy and/or islet cell transplantation.
• Clinically significant laboratory findings, as defined by the protocol.
• Known presence of factors that interfered with the HbA1c measurement.
• History of severe hypoglycemia required emergency room admission or hospitalization within 3 months prior to screening.
• Hospitalization for recurrent diabetic ketoacidosis within 3 months prior to screening.
• Retinopathy or maculopathy with one of the following treatments, either recent (within 3 months of screening) or planned: intravitreal injections or laser or vitrectomy surgery.
• Use of glucose lowering treatments other than the multiple dose injections and basal insulin regimen (including use of insulin pump therapy), within 12 weeks prior to screening.
• Participants had received systemic glucocorticoids for one week or more within 3 months prior to screening (topical, nasal spray, inhaled or intra-articular applications are allowed).
• Participants had received systemic immunosuppressive agents within 6 months prior to screening.
• The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 8400014 — Concord, California, United States
• Investigational Site Number 8400001 — Temecula, California, United States
• Investigational Site Number 8400015 — Ventura, California, United States
• Investigational Site Number 8400010 — Aurora, Colorado, United States
• Investigational Site Number 8400029 — Waterbury, Connecticut, United States
• Investigational Site Number 8400038 — Doral, Florida, United States
• Investigational Site Number 8400030 — Miami, Florida, United States
• Investigational Site Number 8400032 — New Port Richey, Florida, United States
• Investigational Site Number 8400026 — Ocoee, Florida, United States
• Investigational Site Number 8400033 — Palm Harbor, Florida, United States
• Investigational Site Number 8400012 — Atlanta, Georgia, United States
• Investigational Site Number 8400005 — Columbus, Georgia, United States
• Investigational Site Number 8400009 — Roswell, Georgia, United States
• Investigational Site Number 8400019 — Crystal Lake, Illinois, United States
• Investigational Site Number 8400028 — Des Moines, Iowa, United States
• Investigational Site Number 8400018 — Lexington, Kentucky, United States
• Investigational Site Number 8400023 — Baltimore, Maryland, United States
• Investigational Site Number 8400003 — Rockville, Maryland, United States
• Investigational Site Number 8400013 — Waltham, Massachusetts, United States
• Investigational Site Number 8400004 — Flint, Michigan, United States
• Investigational Site Number 8400021 — Kansas City, Missouri, United States
• Investigational Site Number 8400031 — Washington, Missouri, United States
• Investigational Site Number 8400036 — Omaha, Nebraska, United States
• Investigational Site Number 8400017 — Las Vegas, Nevada, United States
• Investigational Site Number 8400007 — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.